Want to see IN:VENUSREM full AI Analyst Report?
VENUSREM Stock Chart & Stats
₹1650.60
-₹77.00(-4.67%)
At close: 4:00 PM EDT
₹1650.60
-₹77.00(-4.67%)
Day’s Range― - ―
52-Week Range₹423.70 - ₹2,043.15
Previous CloseN/A
Volume69.99K
Average Volume (3M)2.91K
Market Cap
₹21.25B
Enterprise Value₹10.13K
Total Cash (Recent Filing)₹1.03B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)18.1
Beta0.85
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.63%
Share Statistics
EPS (TTM)86.91
Shares Outstanding13,366,988
10 Day Avg. Volume2,147
30 Day Avg. Volume2,907
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.65
Price to Sales (P/S)1.42
P/FCF Ratio9.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.9
Revenue Forecast (FY)₹828.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA return to sustained revenue growth across the latest three years indicates improving demand and market traction after the 2023 decline. Continued top-line expansion can support operating scale, strengthen distribution reach, and provide a durable base for future earnings growth.
Conservative Balance SheetVery low leverage and steadily growing equity give Venus Remedies meaningful financial flexibility. A stronger capital base can help fund product development, manufacturing capacity, and market expansion while reducing the balance-sheet pressure that typically limits pharmaceutical companies during weaker periods.
Improved Cash GenerationThe sharp improvement in operating and free cash flow shows that recent earnings growth was accompanied by stronger internal cash generation. This supports reinvestment in pharmaceutical operations, improves resilience, and reduces reliance on external financing for ongoing business needs.
Bears Say
Uncertain Margin SustainabilityMaterial historical gross-margin fluctuations make it difficult to determine how much of the latest profit surge reflects lasting operating improvement. Without 2026 margin detail, earnings durability remains less certain if product mix, pricing, or operating factors change over the next several quarters.
Uneven Cash ConversionDespite the strong 2026 cash-flow result, uneven conversion in earlier years suggests that working-capital or capital-expenditure cycles can affect the timing and quality of reported earnings. This variability may complicate reinvestment planning and reduce confidence in consistently repeatable cash generation.
Debt Level VolatilityLow leverage is a strength, but fluctuations in absolute debt indicate that financing needs have not been completely stable. If borrowing rises alongside expansion or uneven cash conversion, interest obligations and capital-allocation constraints could become more relevant to future financial flexibility.
Venus Remedies Limited News
VENUSREM FAQ
What was Venus Remedies Limited’s price range in the past 12 months?
Venus Remedies Limited lowest stock price was ₹423.70 and its highest was ₹2043.15 in the past 12 months.
What is Venus Remedies Limited’s market cap?
Venus Remedies Limited’s market cap is ₹21.25B.
When is Venus Remedies Limited’s upcoming earnings report date?
Venus Remedies Limited’s upcoming earnings report date is Nov 14, 2026 which is in 55 days.
How were Venus Remedies Limited’s earnings last quarter?
Venus Remedies Limited released its earnings results on Jul 20, 2026. The company reported ₹17.184 earnings per share for the quarter.
Is Venus Remedies Limited overvalued?
According to Wall Street analysts Venus Remedies Limited’s price is currently Overvalued.
Does Venus Remedies Limited pay dividends?
Venus Remedies Limited pays a Notavailable dividend of ₹10 which represents an annual dividend yield of 0.63%. See more information on Venus Remedies Limited dividends here
What is Venus Remedies Limited’s EPS estimate?
Venus Remedies Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Remedies Limited have?
Venus Remedies Limited has 13,366,988 shares outstanding.
What happened to Venus Remedies Limited’s price movement after its last earnings report?
Venus Remedies Limited reported an EPS of ₹17.184 in its last earnings report. Following the earnings report the stock price went down -4.564%.
Which hedge fund is a major shareholder of Venus Remedies Limited?
Currently, no hedge funds are holding shares in IN:VENUSREM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Venus Remedies Limited
Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide spectrum of therapeutic areas, including treatments for pain and fever, diabetes, bacterial infections, cardiovascular conditions, gastrointestinal disorders, neurological ailments, and oncology. Additionally, it provides solutions for respiratory health, skin and wound care, stress management, and urological issues, alongside essential vitamins, minerals, and nutritional supplements. Venus Remedies is also active in the field of antimicrobial resistance, offering specialized products, and it supplies disinfectants and hand sanitizers. Furthermore, the firm maintains a distinct line of herbal products and offers hormones and iron supplements. Established in 1989, Venus Remedies Limited operates from its headquarters in Panchkula, India.
Technical Analysis
Indoco Remedies Limited
―
Ind-Swift Laboratories Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Syncom Formulation (India) Ltd.
―
Windlas Biotech Ltd.
―